These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 34734434)

  • 1. CD155/TIGIT signaling regulates the effector function of tumor-infiltrating CD8+ T cell by NF-κB pathway in colorectal cancer.
    Li S; Ding J; Wang Y; Wang X; Lv L
    J Gastroenterol Hepatol; 2022 Jan; 37(1):154-163. PubMed ID: 34734434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blocking TIGIT/CD155 signalling reverses CD8
    Liu L; Wang A; Liu X; Han S; Sun Y; Zhang J; Guo L; Zhang Y
    J Transl Med; 2022 Jun; 20(1):280. PubMed ID: 35729552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TIGIT Can Exert Immunosuppressive Effects on CD8+ T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro.
    Zhang C; Wang Y; Xun X; Wang S; Xiang X; Hu S; Cheng Q; Guo J; Li Z; Zhu J
    J Immunother; 2020 Oct; 43(8):236-243. PubMed ID: 32804915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD155T/TIGIT Signaling Regulates CD8
    He W; Zhang H; Han F; Chen X; Lin R; Wang W; Qiu H; Zhuang Z; Liao Q; Zhang W; Cai Q; Cui Y; Jiang W; Wang H; Ke Z
    Cancer Res; 2017 Nov; 77(22):6375-6388. PubMed ID: 28883004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.
    Wu L; Mao L; Liu JF; Chen L; Yu GT; Yang LL; Wu H; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Cancer Immunol Res; 2019 Oct; 7(10):1700-1713. PubMed ID: 31387897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immune checkpoint TIGIT/CD155 promotes the exhaustion of CD8 + T cells in TNBC through glucose metabolic reprogramming mediated by PI3K/AKT/mTOR signaling.
    Huang M; Yu X; Wang Q; Jiang Z; Li X; Chen W; Song C
    Cell Commun Signal; 2024 Jan; 22(1):35. PubMed ID: 38216949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of CD155/TIGIT expression in patients with colorectal cancer.
    Murakami D; Matsuda K; Iwamoto H; Mitani Y; Mizumoto Y; Nakamura Y; Matsuzaki I; Iwamoto R; Takahashi Y; Kojima F; Murata SI; Yamaue H
    PLoS One; 2022; 17(3):e0265908. PubMed ID: 35324958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TIGIT and CD155 as Immune-Modulator Receptor and Ligand on CD4
    Kamrani A; Soltani-Zangbar MS; Shiri S; Yousefzadeh Y; Pourakbari R; Aghebati-Maleki L; Mehdizadeh A; Danaii S; Jadidi-Niaragh F; Yousefi B; Kafil HS; Hojjat-Farsangi M; Motavalli R; Zolfaghari M; Haji-Fatahaliha M; Mahmoodpoor A; Ahmadian Heris J; Emdadi A; Yousefi M
    Immunol Invest; 2022 May; 51(4):1023-1038. PubMed ID: 33855917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of aspirin in the prevention of colorectal cancer through TIGIT-CD155 pathway.
    Ma B; Duan X; Zhou Q; Liu J; Yang X; Zhang D; Yang S; Du Y; Li H; Su C
    J Cell Mol Med; 2019 Jul; 23(7):4514-4522. PubMed ID: 31090213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signaling.
    Li M; Xia P; Du Y; Liu S; Huang G; Chen J; Zhang H; Hou N; Cheng X; Zhou L; Li P; Yang X; Fan Z
    J Biol Chem; 2014 Jun; 289(25):17647-57. PubMed ID: 24817116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.
    Josefsson SE; Huse K; Kolstad A; Beiske K; Pende D; Steen CB; Inderberg EM; Lingjærde OC; Østenstad B; Smeland EB; Levy R; Irish JM; Myklebust JH
    Clin Cancer Res; 2018 Feb; 24(4):870-881. PubMed ID: 29217528
    [No Abstract]   [Full Text] [Related]  

  • 12. Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.
    Inozume T; Yaguchi T; Furuta J; Harada K; Kawakami Y; Shimada S
    J Invest Dermatol; 2016 Jan; 136(1):255-63. PubMed ID: 26763445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TIGIT-Fc alleviates acute graft-versus-host disease by suppressing CTL activation via promoting the generation of immunoregulatory dendritic cells.
    Zhang D; Hu W; Xie J; Zhang Y; Zhou B; Liu X; Zhang Y; Su Y; Jin B; Guo S; Zhuang R
    Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):3085-3098. PubMed ID: 29960041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TIGIT and PD-1 may serve as potential prognostic biomarkers for gastric cancer.
    Xu D; Zhao E; Zhu C; Zhao W; Wang C; Zhang Z; Zhao G
    Immunobiology; 2020 May; 225(3):151915. PubMed ID: 32122675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-expression of PD-1 with TIGIT or PD-1 with TIM-3 on tumor-infiltrating CD8
    Meyiah A; Mahmoodi Chalbatani G; Al-Mterin MA; Malekraeisi MA; Murshed K; Elkord E
    Int Immunopharmacol; 2023 Jun; 119():110207. PubMed ID: 37099940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long Noncoding RNA KCNQ1OT1 is a Prognostic Biomarker and mediates CD8
    Lin ZB; Long P; Zhao Z; Zhang YR; Chu XD; Zhao XX; Ding H; Huan SW; Pan YL; Pan JH
    Int J Biol Sci; 2021; 17(7):1757-1768. PubMed ID: 33994860
    [No Abstract]   [Full Text] [Related]  

  • 17. Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma.
    Duan X; Liu J; Cui J; Ma B; Zhou Q; Yang X; Lu Z; Du Y; Su C
    Mol Med Rep; 2019 Oct; 20(4):3773-3781. PubMed ID: 31485637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
    Ma H; Chen X; Mo S; Mao X; Chen J; Liu Y; Lu Z; Yu S; Chen J
    Theranostics; 2023; 13(13):4601-4614. PubMed ID: 37649613
    [No Abstract]   [Full Text] [Related]  

  • 19. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
    Chauvin JM; Ka M; Pagliano O; Menna C; Ding Q; DeBlasio R; Sanders C; Hou J; Li XY; Ferrone S; Davar D; Kirkwood JM; Johnston RJ; Korman AJ; Smyth MJ; Zarour HM
    Clin Cancer Res; 2020 Oct; 26(20):5520-5533. PubMed ID: 32591463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The TIGIT/CD226 axis regulates human T cell function.
    Lozano E; Dominguez-Villar M; Kuchroo V; Hafler DA
    J Immunol; 2012 Apr; 188(8):3869-75. PubMed ID: 22427644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.